A Patient-Friendly Guide to Gene Therapy for Inherited Retinal Diseases

Retinal gene therapy is an exciting and rapidly advancing treatment designed to help patients with certain inherited retinal diseases (IRDs). These are genetic conditions caused by changes, called mutations, in genes that are important for normal retinal function. Gene therapy aims to address the underlying genetic problem rather than only treating symptoms. Although not every inherited retinal disease currently has an approved treatment, major advances in research and clinical trials are creating new possibilities for preserving and improving vision.

The retina is the thin layer of nerve tissue lining the back of the eye that captures light and sends visual information to the brain so we can see. Within the retina are specialized cells called photoreceptors, including rods and cones. Rods help us see in dim lighting and support side vision, while cones help with color vision and fine detail. When certain genes do not work properly, these cells may gradually lose function, leading to progressive vision loss.

Inherited retinal diseases include conditions such as retinitis pigmentosa, Leber congenital amaurosis (LCA), Stargardt disease, choroideremia, X-linked retinoschisis, cone-rod dystrophy, and many others. Symptoms may include night blindness, reduced side vision (“tunnel vision”), blurry central vision, light sensitivity, difficulty adapting to darkness, or progressive vision loss over time.

Gene therapy works by delivering healthy genetic material to retinal cells to help restore or preserve function. In some cases, the goal is to replace a missing or defective gene. In other approaches, therapy may aim to slow degeneration, improve cell survival, or make remaining retinal cells more responsive to light. Because inherited retinal diseases vary widely, treatments are tailored to the specific gene involved.

Currently, one FDA-approved retinal gene therapy exists: Luxturna (voretigene neparvovec-rzyl), which is approved for selected patients with inherited retinal disease caused by mutations in the RPE65 gene. Luxturna works by delivering a functional copy of the RPE65 gene into retinal cells to help improve retinal function. However, only certain patients qualify based on genetic testing, retinal structure, and disease stage.

Many gene therapies are delivered through a specialized retinal surgery called subretinal injection. During surgery, a retina specialist creates a small temporary space beneath the retina and carefully delivers the therapy directly to the targeted retinal cells. Some emerging therapies may use injections into the vitreous (the gel inside the eye) rather than under the retina. Recovery depends on the specific treatment and whether surgery is involved.

Determining whether a patient may qualify for retinal gene therapy usually requires specialized testing. Retina specialists often recommend genetic testing, optical coherence tomography (OCT), fundus autofluorescence (FAF), visual field testing, electroretinography (ERG), and detailed retinal imaging. Genetic counseling can also help families better understand inheritance patterns and eligibility for treatment or clinical trials.

Although retinal gene therapy offers tremendous promise, it is important to understand that not every patient is currently eligible and outcomes vary depending on the disease and timing of treatment. Earlier intervention may preserve more retinal cells before significant damage occurs. Research into gene replacement, gene editing, optogenetics, stem cells, and neuroprotective therapies continues to expand rapidly.

For many patients and families, retinal gene therapy represents hope for preserving vision and potentially slowing disease progression. Regular follow-up with a retina specialist experienced in inherited retinal diseases is important to stay informed about new treatment opportunities and clinical trials.